Abstract. The present study aimed to investigate the expression status and clinical implications of DEK in breast cancer, in order to contribute to developments in breast cancer management. DEK expression status was detected in 628 breast cancer specimens by western blot analysis and immunohistochemistry staining, and the correlation between DEK protein and clinico-pathological parameters and prognosis of breast cancer was subsequently determined. In comparison to para-carcinoma tissues, DEK protein was highly expressed in breast cancer specimens and was correlated with chemotherapy resistance. In total, 61.94% (389/628) of breast cancer cases exhibited high expression of DEK. According to universal analysis, it was observed that age, tumor size, histological grade, metastatic nodes and distant metastasis (P=0.024, 0.001, 0.001, 0.001 and 0.001 respectively) are key factors associated with DEK. Furthermore, compared with samples with no or low DEK protein expression, high DEK expression resulted in a significantly increased distant metastasis rate and poor disease-specific survival (P= 0.001). In addition, DEK protein was detected as an independent prognostic factor (P=0.001) in the Cox regression analysis. DEK was correlated with chemotherapy resistance and may be an independent prognostic factor for breast cancer, as well as a potential therapeutic target.
Introduction
According to the World Health Organization, the number of individuals diagnosed with cancer annually has reached >1.2 million individuals, and breast cancer is responsible for 3% of female fatalities (1, 2) . Although a number of identified molecules are involved in the way breast cancers progress and metastasize, the mechanisms of breast cancer remain to be identified (3, 4) . Surgery is mainly used as a primary treatment, and chemotherapy, radiotherapy and endocrine therapy are then directed at eliminating the residual tumor cells, thus reducing the recurrence and metastasis risk. However, there remain cases of relapse or metastases in certain patients. At this point, few molecules exhibit high efficiency in predicting chemotherapy sensitivity and postoperative distant metastasis for breast cancer.
DEK, a non-histone nuclear phosphoprotein initially identified as a putative proto-oncogene, has recently been found to be associated with the regulation of hematopoiesis (5) . Studies have demonstrated that not only is it associated with chromatin reconstruction and gene transcription, but it also contributes to cell apoptosis (5-7). Thus, there is a direct correlation between high expression levels of the human DEK and numerous types of human malignancy (5) . Following investigation of the DEK expression level in chronic lymphocytic leukemia, Wang et al (6) observed a marked increase of DEK mRNA expression in patients with chronic lymphocytic leukemia, which may be useful to assess the prognosis in patients with chronic lymphocytic leukemia. At present, the DEK expression status and the clinical implication in breast cancer remain unclear. Thus, the present study aimed to investigate the expression status of DEK in breast cancer and the clinical implications in order to aid in the development of breast cancer management.
Patients and methods
Patients and tissue specimens. Patients (n=628) with histologically confirmed breast cancer who underwent radical surgery between January 2001 and January 2010 in Harbin Medical University (Nangang, China) were enrolled in the present study. Samples were obtained for immunohistochemical staining as well as prognostic analysis. The mean age of the patients was 47.28±9.43 years (range, 27-78 years). Patients underwent curative surgery, the resected specimens were pathologically examined and >10 lymph nodes were pathologically examined following surgery. Complete medical records including the ER, PR, Her2, p53 and Ki67 status were available. The study protocol was approved by Harbin Medical University. Patients were informed of the details of the study and agreed to participate. Immunohistochemistry procedures. Thin slices of tumor tissue from all cases were fixed in 4% formaldehyde solution (pH 7.0) for periods not exceeding 24 h. Paraffin embedding was conducted, and 4 µm-thick sections were cut and placed on glass slides coated with 3-aminopropyl triethoxysilane (Seebio Biotech Inc., Shanghai, China) for immunohistochemistry. Tissue samples were stained with hematoxylin and eosin to determine histological type and grade of tumors. Briefly, breast tumor tissues were cut at a thickness of 4 µm using a cryostat. The sections were mounted on microscope slides, air-dried and then fixed in a mixture of 50% acetone and 50% methanol. The sections were then de-waxed with xylene, gradually hydrated with gradient alcohol, and washed with phosphate-buffered saline (PBS). Sections were incubated for 60 min with the primary antibody. Following washing with PBS, sections were incubated for 30 min with the secondary biotinylated antibody (Multilink Swine anti-goat/mouse/ rabbit immunoglobulin; Dako Inc., Carpinteria, CA, USA). Following washing, Avidin Biotin Complex (1:1,000 dilution, Vector Laboratories Ltd., Burlingame, CA, USA) was then applied to the sections for 30-60 min at room temperature. The immunoreactive products were visualized by catalysis of 3, 3-diaminobenzidine (DAB) by horseradish peroxidase in the presence of H 2 O 2 , following extensive washings. Sections were then counterstained in Gill's hematoxylin and dehydrated in ascending grades of methanol prior to clearing in xylene, and mounting under a coverslip. The sections were observed under an Olympus CX31 microscope (Olympus, Tokyo, Japan).
DEK
To score DEK as immunopositive staining, the positive cells are shown as a yellow to brown color in the nucleus and/or cytoplasm. DEK expression was classified semi-quantitatively according to the following criteria: -, <1% of neoplastic cells discretely expressed DEK; +, ≥1 of morphologically unequivocal neoplastic cells discretely expressed DEK. The factors associated with post-operative distant metastasis with multiple analyses were also investigated. Age, tumor size, histological type, triple negative subtype and DEK expression were found to be associated with post-operative distant metastasis in breast cancer (Table II) . In addition, the present study investigated the correlation between DEK expression and chemotherapeutic sensitivity in 107 patients with breast cancer who underwent neoadjuvant chemotherapy. DEK expression was expressed in 78.57, 67.86, 46.30 and 18.18% of patients with complete response (CR), partial response (PR), stable disease (SD) and progressive disease (PD) (P=0.006; Table III) .
Prognostic analysis. Furthermore, DEK along with age, histological type, lymph node metastasis, affected survival rate in triple-negative breast cancer. Patients with triple-negative breast cancer and high DEK expression exhibited a poorer disease-specific survival compared with those with none or low expressed DEK protein (P= 0.001; Fig. 3 ). In the Cox regression test, DEK protein was detected as an independent prognostic factor (P=0.001; Table IV) .
Discussion
DEK is a chromatin-associated oncogene whose expression has been linked to cancer through multiple mechanisms, including β-catenin activity. Recently, Privette reported that DEK is a downstream target of Ron receptor activation in murine and human models (7) . The absence of DEK in the MMTV-Ron mouse model led to a significant delay in tumor development, characterized by decreased cell proliferation, diminished metastasis and a decline in the number of cells expressing breast cancer stem cell markers. Overexpression of DEK was sufficient to promote cellular growth and invasion in cell lines established from MMTV-Ron mouse models (7). In another (8) . DEK is also found to be related to the poor prognosis of gastric cancer and colorectal cancer (9, 10) . Thus, DEK may exhibit potential as a breast cancer treatment target. At present, the expression status of DEK protein in breast cancer and its correlation with the biological behavior of breast cancer remains unclear. Furthermore, studies addressing the association between DEK and chemotherapy sensitivity and prognosis of breast cancer are limited. In the present study, the correlation between DEK expression and the biological behavior and clinicopathological characteristics of breast cancer was investigated. DEK protein expression was observed to be significantly higher in cancerous tissues than adjacent-tumor tissues. Furthermore, DEK protein was found to be related to tumor size, histological type, lymph node metastasis and post-operative distant metastasis in the 628 breast cancers. Following further investigation of the association between DEK expression and chemotherapeutic sensitivity, it was found that DEK expression was significantly correlated with poor chemotherapy response in breast neoadjuvant chemotherapy. 
C B A
After survival analysis, cases with high-level DEK expression were significantly more likely to develop post-operative distant metastasis and exhibit poor postoperative disease specific survival. Cox regression analysis showed DEK protein was detected as an independent prognostic factor. The outcomes suggested that DEK expression has been shown to be associated with poor breast cancer prognosis. DEK may be involved in breast cancer oncogenesis and may be a potential biomarker for the metastasis and chemotherapy resistance of breast cancer.
